Project Grant R01CA293642
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$690K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides funding of $107,948 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at "deconvoluting the contributions of the IFNγ pathway components to lung tumor microenvironment and tumor immunity".
The key objectives include:
Investigating the influence of SOCS1 knockout on tumor immune composition and phenotype in a mouse lung cancer model using novel...
This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), is supporting research to elucidate the cellular and molecular mechanisms driving age-associated pro-tumoral myelopoiesis. The $680,334 award, effective from March 1, 2025 through February 28, 2030, will enable the Icahn School of Medicine at Mount Sinai to conduct high-dimensional profiling of tumors from an early-stage lung cancer patient cohort, perform...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $121,460 to The Research Foundation For The State University Of New York, doing business as Stony Brook University, to conduct research on the interaction between the proteins NRF2 and PRMT5 in lung cancer. The research aims to biochemically characterize this interaction, determine how PRMT5-mediated repression of NRF2 activity impacts lung cancer growth, and evaluate the potential of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $530,786 to The Leland Stanford Junior University to conduct research focused on modulating cysteine metabolism to induce cell death in small cell lung cancer (SCLC). The key objectives are to:
Determine how distinct neuroendocrine SCLC cell states dictate the choice to die by apoptosis versus ferroptosis, focusing on the role of the GCN2/ATF4 amino acid sensing pathway and...
This Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) provides $256,487 to the Sloan-Kettering Institute for Cancer Research in New York to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes. The research aims to improve risk stratification and clinical management of NSCLC by leveraging real-world data from sources like circulating tumor DNA sequencing, radiomics, tumor genomics, and clinical notes....
This Project Grant award of $1,545,074 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at Yale University to uncover metabolic vulnerabilities in non-small cell lung cancer (NSCLC) driven by specific genetic mutations. The key objectives are to:
Interrogate the mechanistic basis of serine-glycine one carbon (SGOC) metabolism dependence, particularly the role of serine hydroxymethyltransferase (SHMT) enzymes, in NSCLC cells harboring KRAS...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $281,370 to support research efforts at The Ohio State University aimed at overcoming immunotherapy resistance in lung cancers with STK11 gene mutations. The key products and services to be delivered under this 5-year award include:
Validation of the STK11-MLDD biomarker to predict patient response to immune checkpoint blockade (ICB) therapies in STK11-deficient lung...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is supporting research aimed at developing effective therapeutic strategies for lung cancers with SMARCA4 genetic deficiencies. The primary grantee, The Trustees of Columbia University in the City of New York, will receive $557,418 over the award period from March 2025 to February 2030. The research will use genetically engineered mouse models to assess the impact of...
This federal Project Grant award, totaling $701,876 and funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), will support a research project titled "A Systems-Level Approach to Therapeutically Target STING in Cancer" at Weill Medical College of Cornell University. The project aims to utilize a novel technology called SatSeq to map the structure-function landscape of the immune-related protein STING and its role in cancer progression. Specifically, the...
The National Cancer Institute (NCI) awarded a $703,410 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to New York University (NYU) School of Medicine. The grant, awarded on January 16, 2025, supports a comprehensive research program aimed at understanding and disrupting the adenocarcinoma-to-squamous-cell transition, a cellular plasticity mechanism that enables resistance to KRAS inhibitor therapies in non-small cell lung cancer.
The research involves conducting a...